Eucalyptol

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Eucalyptol
Accession Number
DB03852  (EXPT00969)
Type
Small Molecule
Groups
Experimental, Nutraceutical
Description

Eucalyptol is naturally produced cyclic ether and monoterpenoid. Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro.

Structure
Thumb
Similar Structures
Synonyms
  • 1,8-cineol
  • 1,8-Cineole
  • 1,8-epoxy-p-menthane
  • 1,8-oxido-p-menthane
  • Cajeputol
  • Cineole
  • Eucalyptol
  • Zineol
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Unlock Additional Data
Rosatra Synergy for treatment of Acne RosaceaOil0.7 g/50gTopicalPhytopia Co., Ltd.2016-02-29Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Advanced AntisepticEucalyptol (.092 kg/100L) + Levomenthol (.042 kg/100L) + Methyl salicylate (.060 kg/100L) + Thymol (.064 kg/100L)MouthwashOralDemoulas Supermarkets, Inc.2010-07-22Not applicableUs
Advanced AntisepticEucalyptol (.042 mL/100L) + Levomenthol (.042 mL/100L) + Methyl salicylate (.060 mL/100L) + Thymol (.064 mL/100L)MouthwashOralWakfern Food Corporation2010-11-24Not applicableUs
Advanced Antiseptic CitrusEucalyptol (.092 mL/100L) + Levomenthol (.042 mL/100L) + Methyl salicylate (.060 mL/100L) + Thymol (.042 mL/100L)MouthwashOralH.E.B.2010-10-15Not applicableUs
Advanced Antiseptic CitrusEucalyptol (.092 mL/100L) + Levomenthol (.042 mL/100L) + Methyl salicylate (.060 mL/100L) + Thymol (.042 mL/100L)MouthwashOralDrug Mart1991-06-15Not applicableUs
Advanced CitrusEucalyptol (.092 kg/100L) + Levomenthol (.042 kg/100L) + Methyl salicylate (.060 kg/100L) + Thymol (.064 kg/100L)MouthwashOralWalmart Stores2010-07-22Not applicableUs
Advanced Citrus AntisepticEucalyptol (.092 mL/100L) + Levomenthol (.042 mL/100L) + Methyl salicylate (.060 mL/100L) + Thymol (.064 mL/100L)MouthwashOralPublix Supermarkets, Inc.2001-05-03Not applicableUs
Amber Mouth RinseEucalyptol (0.92 mg/1mL) + Levomenthol (0.42 mg/1mL) + Methyl salicylate (0.6 mg/1mL) + Thymol (0.64 mg/1mL)LiquidOralFilo America2013-07-30Not applicableUs
Anitseptic Mouth RinseEucalyptol (0.92 mg/1mL) + Levomenthol (0.42 mg/1mL) + Methyl salicylate (0.60 mg/1mL) + Thymol (0.64 mg/1mL)MouthwashOralPharmacy Value Alliance LLC2003-08-19Not applicableUs
AntisepticEucalyptol (0.92 mg/1mL) + Levomenthol (0.42 mg/1mL) + Methyl salicylate (0.60 mg/1mL) + Thymol (0.64 mg/1mL)RinseOralDza Brands,2008-02-05Not applicableUs
AntisepticEucalyptol (0.92 mg/1mL) + Levomenthol (0.42 mg/1mL) + Methyl salicylate (0.60 mg/1mL) + Thymol (0.64 mg/1mL)MouthwashOralTARGET Corporation1996-07-15Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AntisepticEucalyptol (.092 kg/100L) + Levomenthol (.042 kg/100L) + Menthyl salicylate (.060 kg/100L) + Thymol (.064 kg/100L)MouthwashOralDuane Reade2006-08-08Not applicableUs
Antiseptic RinseEucalyptol (.092 kg/100L) + Levomenthol (.042 kg/100L) + Methyl salicylate (.060 kg/100L) + Thymol (.064 kg/100L)MouthwashOralMeijer2006-08-08Not applicableUs
Categories
UNII
RV6J6604TK
CAS number
470-82-6
Weight
Average: 154.2493
Monoisotopic: 154.135765198
Chemical Formula
C10H18O
InChI Key
WEEGYLXZBRQIMU-WAAGHKOSSA-N
InChI
InChI=1S/C10H18O/c1-9(2)8-4-6-10(3,11-9)7-5-8/h8H,4-7H2,1-3H3/t8-,10+
IUPAC Name
(1s,4s)-1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane
SMILES
C[C@@]12CC[C@@H](CC1)C(C)(C)O2

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Unlock Additional Data
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral, rat LD50: 2480 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Bastos VP, Gomes AS, Lima FJ, Brito TS, Soares PM, Pinho JP, Silva CS, Santos AA, Souza MH, Magalhaes PJ: Inhaled 1,8-cineole reduces inflammatory parameters in airways of ovalbumin-challenged Guinea pigs. Basic Clin Pharmacol Toxicol. 2011 Jan;108(1):34-9. doi: 10.1111/j.1742-7843.2010.00622.x. Epub 2010 Aug 16. [PubMed:20722639]
External Links
KEGG Drug
D04115
KEGG Compound
C09844
PubChem Compound
2758
PubChem Substance
46506161
ChemSpider
21111689
ChEBI
27961
ChEMBL
CHEMBL1231862
PharmGKB
PA449555
Guide to Pharmacology
GtP Drug Page
HET
CNL
Wikipedia
Eucalyptol
ATC Codes
R05CA13 — Cineole
PDB Entries
1t2b / 3be0 / 4fmx / 4fyz / 4l6g / 4l77 / 4lht
MSDS
Download (74.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentCoughing1
4CompletedPreventionNeonatal Infections1
4CompletedTreatmentPeriodontitis, Aggressive1
Not AvailableRecruitingTreatmentPeriodontitis / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
RinseOral
MouthwashOral
MouthwashBuccal
OintmentNasal
LotionTopical
SprayTopical
PowderTopical
SuppositoryRectal
LiquidIntramuscular
LozengeOral
MouthwashDental; Oral
LiquidOral
OilTopical0.7 g/50g
OilTopical
MouthwashDental
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)1.5 °CPhysProp
boiling point (°C)176.4 °CPhysProp
water solubility3500 mg/L (at 21 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.74GRIFFIN,S ET AL. (1999)
Predicted Properties
PropertyValueSource
Water Solubility0.0225 mg/mLALOGPS
logP3.36ALOGPS
logP2.35ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity45.86 m3·mol-1ChemAxon
Polarizability18.54 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.988
Blood Brain Barrier+0.9842
Caco-2 permeable+0.7609
P-glycoprotein substrateSubstrate0.5435
P-glycoprotein inhibitor INon-inhibitor0.6374
P-glycoprotein inhibitor IINon-inhibitor0.6455
Renal organic cation transporterNon-inhibitor0.7847
CYP450 2C9 substrateNon-substrate0.8132
CYP450 2D6 substrateNon-substrate0.7839
CYP450 3A4 substrateSubstrate0.5962
CYP450 1A2 substrateNon-inhibitor0.7719
CYP450 2C9 inhibitorNon-inhibitor0.7571
CYP450 2D6 inhibitorNon-inhibitor0.95
CYP450 2C19 inhibitorNon-inhibitor0.658
CYP450 3A4 inhibitorNon-inhibitor0.9395
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9399
Ames testNon AMES toxic0.9574
CarcinogenicityNon-carcinogens0.7856
BiodegradationNot ready biodegradable0.8549
Rat acute toxicity1.8144 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8743
hERG inhibition (predictor II)Non-inhibitor0.7089
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0536-9200000000-aa52695ff4a2c1313e0b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxanes. These are compounds containing an oxane (tetrahydropyran) ring, which is a six-member saturated aliphatic heterocycle with one oxygen atom and five carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxanes
Sub Class
Not Available
Direct Parent
Oxanes
Alternative Parents
Oxacyclic compounds / Dialkyl ethers / Hydrocarbon derivatives
Substituents
Oxane / Oxacycle / Ether / Dialkyl ether / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Aliphatic heteropolycyclic compound
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
cineole (CHEBI:27961)

Drug created on June 13, 2005 07:24 / Updated on May 09, 2019 00:08